论文部分内容阅读
目的:观察艾迪注射液在蒽环类耐药的转移性乳腺癌患者化疗过程中的作用。方法:将73例符合标准的晚期乳腺癌患者随机分为治疗组(化疗期间使用艾迪注射液)和对照组(化疗期间不使用艾迪注射液及其他抗肿瘤中成药),观察总有效率(ORR)、疾病控制率(DCR)、肿瘤进展时间(TTP)及各组间不良反应的轻重程度。结果:两组ORR、DCR比较,差异均无统计学意义(P>0.05);治疗组TTP较对照组延长(P<0.05);治疗组出现Ⅲ、Ⅳ度白细胞降低及Ⅰ、Ⅱ度疲乏不适患者较对照组少(P<0.05),Ⅰ、Ⅱ度过敏反应患者较对照组多(P<0.05)。结论:艾迪注射液对于蒽环类耐药的晚期乳腺癌患者的化疗,在ORR及DCR上并无确切的优势,但可起到延长TTP的作用,还能明显减轻患者化疗后的白细胞降低的严重程度及疲乏无力等不适,但需注意过敏反应的预防及处理。
Objective: To observe the effect of Aidi Injection in the chemotherapy of anthracycline-resistant metastatic breast cancer patients. Methods: Seventy-three patients with advanced breast cancer were randomly divided into treatment group (Aidi injection during chemotherapy) and control group (Aidi injection and other anti-tumor proprietary Chinese medicines were not used during chemotherapy), and the total effective rate (ORR), disease control rate (DCR), tumor progression time (TTP) and the severity of adverse reactions among the groups. Results: There was no significant difference in the ORR and DCR between the two groups (P> 0.05). The TTP of the treatment group was longer than that of the control group (P <0.05). The grade Ⅲ and Ⅳ leukopenia and I / II degree of fatigue discomfort The patients were less than the control group (P <0.05). The patients with grade Ⅰ and Ⅱ hypersensitivity were more than the control group (P <0.05). Conclusion: Aidi injection for anthracycline-resistant patients with advanced breast cancer chemotherapy in the ORR and DCR does not have an exact advantage, but can play the role of prolonging TTP, but also significantly reduce the patient after chemotherapy leukopenia The severity and fatigue and other discomfort, but should pay attention to the prevention and treatment of allergic reactions.